Comparative Pharmacology
Head-to-head clinical analysis: CALDEROL versus HECTOROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALDEROL versus HECTOROL.
CALDEROL vs HECTOROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
None Documented
None Documented
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog